These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 20517307

  • 1. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
    van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P.
    Br J Cancer; 2010 Jun 29; 103(1):29-35. PubMed ID: 20517307
    [Abstract] [Full Text] [Related]

  • 2. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.
    Tumour Biol; 2013 Jun 29; 34(3):1935-47. PubMed ID: 23519841
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.
    J Neurooncol; 2009 Mar 29; 92(1):23-31. PubMed ID: 19011762
    [Abstract] [Full Text] [Related]

  • 4. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.
    J Natl Cancer Inst; 2016 May 29; 108(5):. PubMed ID: 26615020
    [Abstract] [Full Text] [Related]

  • 5. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.
    J Clin Invest; 2012 Jan 29; 122(1):253-66. PubMed ID: 22156195
    [Abstract] [Full Text] [Related]

  • 6. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gónzalez B, Melguizo C.
    PLoS One; 2015 Jan 29; 10(10):e0140131. PubMed ID: 26447477
    [Abstract] [Full Text] [Related]

  • 7. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN.
    Neuro Oncol; 2009 Jun 29; 11(3):281-91. PubMed ID: 18952979
    [Abstract] [Full Text] [Related]

  • 8. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q, Berglund AE, Macaulay RJ, Etame AB.
    Int J Mol Sci; 2023 Oct 14; 24(20):. PubMed ID: 37894860
    [Abstract] [Full Text] [Related]

  • 9. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.
    Pediatr Blood Cancer; 2007 Apr 14; 48(4):403-7. PubMed ID: 16609952
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.
    Neuro Oncol; 2013 Jun 14; 15(6):735-46. PubMed ID: 23479134
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
    Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M.
    PLoS One; 2012 Jun 14; 7(3):e33449. PubMed ID: 22428052
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.
    Neurol Med Chir (Tokyo); 2007 Aug 14; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.